| Source | u |
|---|---|
| Target | Notch 2, Notch 3 |
| Legal status | Investigational |
| Cas number | 1359940-55-8 |
| Atc prefix | none |
| Kegg | D11775 |
| Chemspiderid | none |
| C | 6338 |
| H | 9804 |
| N | 1700 |
| O | 1990 |
| S | 48 |
| Unii | 333YMY788E |
| Synonyms | OMP-59R5 |
Tarextumab (formerly OMP-59R5) is a fully human monoclonal antibody targeting the Notch 2/3 receptors. It is being tested as a possible treatment for cancer. In January 2015, the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer.[1] Two early stage clinical trials have reported encouraging results.[1]
See also
- Notch signaling pathway, e.g. in embryo tissue development
References
- ^ "Tarextumab Gets FDA Orphan Drug Designation for Lung, Pancreatic Cancer". 2015. Archived from the original on 2016-03-04. Retrieved 2015-02-05.